Mandate

VINGE ADVISES BAIN CAPITAL AND BRAVIDA

June 20, 2013

Vinge and Kirkland & Ellis are advising Bain Capital and Bravida in connection with the refinancing of Bravida, which includes the issue of senior secured floating rate notes in the amount of SEK 1.3 billion and EUR 225 million.

Vinge’s team consists of partners Stefan de Hevesy, Christina Kokko and Peter Bäärnhielm together with associates Robin Dangoor, Paul Dali, Charlotta Järnstedt, Andreas Malmberg, Dain Nevonen and Marie Brommesson.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025